Mode
Text Size
Log in / Sign up

sirolimus

12 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of sirolimus

107 trials tracked of sirolimus: 26 in phase 3 or 4 and 7 with published results. The most-cited published study has 1114 citations.

107Trials tracked
26Phase 3 & 4
0Recruiting
7With published results
Phase distribution
Phase 4 12 Phase 3 14 Phase 2 69 Phase 1 4 Other / NA 8
  1. Phase 3 Efficacy and Safety of Sirolimus in LAM Completed · 1,114 cited
  2. Phase 3 Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission Completed · 223 cited
  3. Phase 3 Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy Completed · 148 cited
  4. Phase 3 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Completed · 111 cited
  5. Phase 3 TBI Dose De-escalation for Fanconi Anemia Completed · 109 cited
  6. Phase 3 Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex Completed · 15 cited
Show 44 more trials
  1. Phase 4 Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation Completed · 10 cited
  2. Phase 4 Mycophenolate Mofetil and Rapamycin as Secondary Intervention vs. Continuation of Calcineurin Inhibitors in Patients at Risk for Chronic Renal Allograft Failure Completed
  3. Phase 4 Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients Completed
  4. Phase 4 Study Evaluating Conversion From Tacrolimus to Sirolimus in Stable Kidney Transplant Recipients Receiving Myfortic Completed
  5. Phase 4 Improved Induction and Maintenance Immunosuppression in Kidney Transplantation Completed
  6. Phase 4 Kidney Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Kidney Transplant Recipients Completed
  7. Phase 4 A Study Comparing the Withdrawal of Steroids or Tacrolimus in Kidney Transplant Recipients Completed
  8. Phase 4 Liver Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Sirolimus in Recipients of a Liver Transplant Completed
  9. Phase 4 Comparison of Sirolimus and Azathioprine in Lung Transplantation Completed
  10. Phase 4 Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients Completed
  11. Phase 4 Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients Completed
  12. Phase 4 Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients Completed
  13. Phase 3 Efficacy of Sirolimus-Based, Steroid Avoidance Immunosuppression African Americans Completed
  14. Phase 3 Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome Completed
  15. Phase 3 Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes Completed
  16. Phase 3 De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma Completed
  17. Phase 3 Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma Completed
  18. Phase 3 Study Comparing Conversion to Sirolimus vs. Continued Use of Calcineurin Inhibitors in Kidney Transplant Recipients Completed
  19. Phase 3 Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) Completed
  20. Phase 3 Study Evaluating Sirolimus in Kidney Transplant Recipients Completed
  21. Phase 2 Sirolimus and Thymoglobulin to Prevent Kidney Transplant Rejection Completed
  22. Phase 2 In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis Completed
  23. Phase 2 Examining the Impact of Sirolimus on Ketamine's Antidepressant Effects Completed
  24. Phase 2 Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease Completed
  25. Phase 2 Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes Completed
  26. Phase 2 Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer Completed
  27. Phase 2 Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer Completed
  28. Phase 2 Islet Transplantation for Type 1 Diabetes Completed
  29. Phase 2 Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies Completed
  30. Phase 2 Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention Completed
  31. Phase 2 Sirolimus in Conjunction With Eylea vs Eylea Alone for Exudative AMD Completed
  32. Phase 2 Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas Completed
  33. Phase 2 Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients Completed
  34. Phase 2 Rapalogues for Autism Phenotype in TSC: A Feasibility Study Completed
  35. Phase 2 Pilot Study of the Evaluation of Subconjunctival Sirolimus in the Treatment of Bilateral GA Associated With AMD Completed
  36. Phase 2 SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors Completed
  37. Phase 2 Sirolimus Injections for Autoimmune Scleritis Completed
  38. Phase 2 Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant Completed
  39. Phase 2 Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy Completed
  40. Phase 2 Sirolimus and Familial Adenomatous Polyposis (FAP) Completed
  41. Phase 2 Topical Rapamycin to Erase Angiofibromas in TSC Completed
  42. Phase 2 UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Completed
  43. Phase 2 A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation Completed
  44. Phase 2 A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas Completed

Showing the 50 most-cited and recently-updated of 107 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.